Sign in
Not yet recruitingPhase 1

Comparing two versions of a drug for peripheral arterial disease in healthy volunteers

Compares how the body handles AJU-B718 and B718R in healthy adults.

Key facts

Who runs it
AJU Pharm Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions
Status
Not yet recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
Nov 2026
Expected to end
Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Test Drug
  • Reference Drug
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults to compare how the body takes up AJU-B718 and B718R, and how safe they are. The drugs are taken on an empty stomach.

Age
19 to less than 65 years
Sex
All sexes can join
Disease stage
Healthy volunteers without clinically significant congenital or chronic diseases
Earlier treatment
People cannot join if they used prohibited or possibly interfering medicines within the set period before the first dose.
Biomarker or test result
BMI 18 to 30 kg/m². Body weight ≥50 kg (110 lb) for males and ≥45 kg (99 lb) for females. Screening test results must allow joining.

Main reasons for not taking part

  • Too much alcohol within 1 month before the first dose
  • Another trial with a study drug within 6 months before the first dose, or blood donation within the set period
  • Past stomach or bowel surgery that may affect how the drug is absorbed
  • Clinically significant bleeding disorders or psychiatric disorders
  • Pregnancy, suspected pregnancy, or breastfeeding

This trial only enrols healthy participants. The registry sentence this rests on: * Healthy adults without clinically significant congenital or chronic diseases.

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 19 to less than 65 years at screening
  • Healthy adults without clinically significant congenital or chronic diseases
  • Considered eligible based on screening test results
  • BMI 18 to 30 kg/m², with body weight ≥50 kg for males and ≥45 kg for females
  • Provided written informed consent
  • Willing to comply with the specified contraception and reproductive restrictions

Who cannot take part

  • Use of prohibited or potentially interfering medications within the specified period prior to the first administration
  • Excessive alcohol consumption within 1 month prior to the first administration
  • Participation in another clinical trial involving administration of an investigational product within 6 months prior to the first administration
  • Blood donation within the specified period prior to the first administration
  • History of gastrointestinal surgery that may affect drug absorption
  • Clinically significant bleeding disorders or other medical conditions that may affect study participation
  • History of clinically significant psychiatric disorders
  • Considered unsuitable for study participation by the Investigator or delegated physician
  • Pregnancy, suspected pregnancy, or breastfeeding in female participants

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the bioequivalence and safety of AJU-B718 and B718R in Healthy Adults.

The 2 groups in the trial

  • Sequence ATreatment being tested

    Period 1: Reference Drug, Single dose / Period 2: Test Drug, Single dose / Period 3: Reference Drug, Single dose / Period 4: Test Drug, Single dose

    Treatment: Test Drug and Reference Drug

  • Sequence BTreatment being tested

    Period 1: Test Drug, Single dose / Period 2: Reference Drug, Single dose / Period 3: Test Drug, Single dose / Period 4: Reference Drug, Single dose

    Treatment: Test Drug and Reference Drug

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open-Label, Fasting, Single-Dose, Oral, 2-Group, 4-Period, Replicate Crossover Study to Evaluate the Bioequivalence and Safety of AJU-B718 and B718R in Healthy Adult Volunteers
Plain-language title
Comparing two versions of a drug for peripheral arterial disease in healthy volunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07901088, who can take part
Record updated
28 October 2026